Treats acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. ANDA 208485, held by Meitheal. Cytarabine.
As of Nov 16, 2026, ANDA 208485 (Cytarabine), held by Meitheal, was first approved by FDA on Feb 28, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Cytarabine in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cytarabine20MG/ML · injectable;injection | Cytarabine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters